These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 37208329)
41. The deubiquitinating enzyme Usp5 regulates Notch and RTK signaling during Drosophila eye development. Ling X; Huang Q; Xu Y; Jin Y; Feng Y; Shi W; Ye X; Lin Y; Hou L; Lin X FEBS Lett; 2017 Mar; 591(6):875-888. PubMed ID: 28140449 [TBL] [Abstract][Full Text] [Related]
42. USP5 promotes breast cancer cell proliferation and metastasis by stabilizing HIF2α. Huang W; Liu X; Zhang Y; Deng M; Li G; Chen G; Yu L; Jin L; Liu T; Wang Y; Chen Y J Cell Physiol; 2022 Apr; 237(4):2211-2219. PubMed ID: 35102545 [TBL] [Abstract][Full Text] [Related]
43. USP5 Sustains the Proliferation of Glioblastoma Through Stabilization of CyclinD1. Li G; Yang T; Chen Y; Bao J; Wu D; Hu X; Feng C; Xu L; Li M; Li G; Jin M; Xu Y; Zhang R; Qian G; Pan J Front Pharmacol; 2021; 12():720307. PubMed ID: 34483932 [TBL] [Abstract][Full Text] [Related]
44. Ubiquitin-specific protease 5 promotes bladder cancer progression through stabilizing Twist1. Cai H; Ke ZB; Chen JY; Li XD; Zhu JM; Xue YT; Ruan ZT; Wang Z; Lin F; Zheng QS; Wei Y; Xue XY; Xu N Oncogene; 2024 Mar; 43(10):703-713. PubMed ID: 38218898 [TBL] [Abstract][Full Text] [Related]
45. UFL1 ablation in T cells suppresses PD-1 UFMylation to enhance anti-tumor immunity. He C; Xing X; Chen HY; Gao M; Shi J; Xiang B; Xiao X; Sun Y; Yu H; Xu G; Yao Y; Xie Z; Xing Y; Budiarto BR; Chen SY; Gao Y; Lee YR; Zhang J Mol Cell; 2024 Mar; 84(6):1120-1138.e8. PubMed ID: 38377992 [TBL] [Abstract][Full Text] [Related]
47. A ubiquitin shuttle DC-UbP/UBTD2 reconciles protein ubiquitination and deubiquitination via linking UbE1 and USP5 enzymes. Song AX; Yang H; Gao YG; Zhou CJ; Zhang YH; Hu HY PLoS One; 2014; 9(9):e107509. PubMed ID: 25207809 [TBL] [Abstract][Full Text] [Related]
48. Therapeutic targeting of the USP2-E2F4 axis inhibits autophagic machinery essential for zinc homeostasis in cancer progression. Xiao W; Wang J; Wang X; Cai S; Guo Y; Ye L; Li D; Hu A; Jin S; Yuan B; Zhou Y; Li Q; Tong Q; Zheng L Autophagy; 2022 Nov; 18(11):2615-2635. PubMed ID: 35253629 [TBL] [Abstract][Full Text] [Related]
50. Deubiquitinating enzyme OTUB1 promotes cancer cell immunosuppression via preventing ER-associated degradation of immune checkpoint protein PD-L1. Zhu D; Xu R; Huang X; Tang Z; Tian Y; Zhang J; Zheng X Cell Death Differ; 2021 Jun; 28(6):1773-1789. PubMed ID: 33328570 [TBL] [Abstract][Full Text] [Related]
51. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840 [TBL] [Abstract][Full Text] [Related]
52. Identification of interleukin-1 beta as a key mediator in the upregulation of Cav3.2-USP5 interactions in the pain pathway. Stemkowski PL; Garcia-Caballero A; Gadotti VM; M'Dahoma S; Chen L; Souza IA; Zamponi GW Mol Pain; 2017; 13():1744806917724698. PubMed ID: 28741432 [TBL] [Abstract][Full Text] [Related]
53. FBW7-mediated ubiquitination and destruction of PD-1 protein primes sensitivity to anti-PD-1 immunotherapy in non-small cell lung cancer. Liu J; Wei L; Hu N; Wang D; Ni J; Zhang S; Liu H; Lv T; Yin J; Ye M; Song Y J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36104103 [TBL] [Abstract][Full Text] [Related]
55. A Synthetically Accessible Small-Molecule Inhibitor of USP5-Cav3.2 Calcium Channel Interactions with Analgesic Properties. Garcia-Caballero A; Gadotti VM; Ali MY; Bladen C; Gambeta E; Van Humbeck JF; MacCallum JL; Zamponi GW ACS Chem Neurosci; 2022 Feb; 13(4):524-536. PubMed ID: 35113527 [TBL] [Abstract][Full Text] [Related]
56. USP5 Stabilizes IKBKG Through Deubiquitination to Suppress Ferroptosis and Promote Growth in Non-small Cell Lung Cancer. Li Y; Qiu G; Zhou M; Chen Q; Liao X Cell Biochem Biophys; 2024 Oct; ():. PubMed ID: 39397222 [TBL] [Abstract][Full Text] [Related]
57. USP8 inhibition reshapes an inflamed tumor microenvironment that potentiates the immunotherapy. Xiong W; Gao X; Zhang T; Jiang B; Hu MM; Bu X; Gao Y; Zhang LZ; Xiao BL; He C; Sun Y; Li H; Shi J; Xiao X; Xiang B; Xie C; Chen G; Zhang H; Wei W; Freeman GJ; Shu HB; Wang H; Zhang J Nat Commun; 2022 Mar; 13(1):1700. PubMed ID: 35361799 [TBL] [Abstract][Full Text] [Related]
58. Overexpression of USP5 contributes to tumorigenesis in non-small cell lung cancer via the stabilization of β-catenin protein. Ma X; Qi W; Pan H; Yang F; Deng J Am J Cancer Res; 2018; 8(11):2284-2295. PubMed ID: 30555744 [TBL] [Abstract][Full Text] [Related]
59. PD-1 regulation in immune homeostasis and immunotherapy. Gao M; Shi J; Xiao X; Yao Y; Chen X; Wang B; Zhang J Cancer Lett; 2024 Apr; 588():216726. PubMed ID: 38401888 [TBL] [Abstract][Full Text] [Related]
60. CRISPR/Cas9-based genome-wide screening for deubiquitinase subfamily identifies USP1 regulating MAST1-driven cisplatin-resistance in cancer cells. Tyagi A; Kaushal K; Chandrasekaran AP; Sarodaya N; Das S; Park CH; Hong SH; Kim KS; Ramakrishna S Theranostics; 2022; 12(13):5949-5970. PubMed ID: 35966591 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]